P06.06.B standardization of therapy and manufacturing using tumor-associated antigen-stimulated autologous dendritic cells co-cultured with cytokine-induced killer cells in cancer immunotherapy

Abstract Background The application of DC-CIK in the field cancer immunotherapy has been shown to be an effective treatment. However, cost treatment is prohibitive for many patients, and lack standard manufacturing processes strategies are main limitations. Material Methods Our experiments used tumor lysate instead cell line as tumor-associated antigen source with DCs co-culture. We provide most efficient method obtaining autologous cells from peripheral blood. Flow cytometry was evaluate activation, CBA assay quantify cytokines secreted by CIK cells, antitumor activity evaluated vitro K562 line. Results demonstrate that process employing frozen Peripheral Blood Mononuclear Cells (PBMCs) can balance patient’s comfort economic benefits. effectively upgrade immunological specificity tumors presence antigen. In showed when number DC: co-cultured 1:20 ratio on 14th day, amount cytokine largest, anti-tumor immune effect potent. When CIK: 25:1 ratio, cytotoxic highest. Conclusion developed activated fashion DC:CIK, established optimal immunologic best model cells.